KR20230022164A - 바독솔론 메틸 또는 이의 유사체를 사용하여 covid-19를 치료하는 방법 - Google Patents

바독솔론 메틸 또는 이의 유사체를 사용하여 covid-19를 치료하는 방법 Download PDF

Info

Publication number
KR20230022164A
KR20230022164A KR1020227041044A KR20227041044A KR20230022164A KR 20230022164 A KR20230022164 A KR 20230022164A KR 1020227041044 A KR1020227041044 A KR 1020227041044A KR 20227041044 A KR20227041044 A KR 20227041044A KR 20230022164 A KR20230022164 A KR 20230022164A
Authority
KR
South Korea
Prior art keywords
patient
compound
groups
alkylamino
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227041044A
Other languages
English (en)
Korean (ko)
Inventor
데보라 퍼거슨
더블유. 크리스찬 위글리
콜린 마이어
제이. 워렌 허프
로버트 엠. 주니어 크랠
Original Assignee
리아타 파마슈티컬즈 홀딩스, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리아타 파마슈티컬즈 홀딩스, 엘엘씨 filed Critical 리아타 파마슈티컬즈 홀딩스, 엘엘씨
Publication of KR20230022164A publication Critical patent/KR20230022164A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020227041044A 2020-05-09 2021-05-07 바독솔론 메틸 또는 이의 유사체를 사용하여 covid-19를 치료하는 방법 Pending KR20230022164A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063022479P 2020-05-09 2020-05-09
US63/022,479 2020-05-09
US202063053056P 2020-07-17 2020-07-17
US63/053,056 2020-07-17
PCT/US2021/031282 WO2021231208A1 (en) 2020-05-09 2021-05-07 Methods of treating covid-19 using bardoxolone methyl or analogs thereof

Publications (1)

Publication Number Publication Date
KR20230022164A true KR20230022164A (ko) 2023-02-14

Family

ID=76197607

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227041044A Pending KR20230022164A (ko) 2020-05-09 2021-05-07 바독솔론 메틸 또는 이의 유사체를 사용하여 covid-19를 치료하는 방법

Country Status (10)

Country Link
US (1) US20230255982A1 (https=)
EP (1) EP4146226A1 (https=)
JP (1) JP2023526567A (https=)
KR (1) KR20230022164A (https=)
AU (1) AU2021273460A1 (https=)
BR (1) BR112022022599A2 (https=)
CA (1) CA3177913A1 (https=)
IL (1) IL298008A (https=)
MX (1) MX2022014034A (https=)
WO (1) WO2021231208A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3240963A1 (en) * 2021-12-23 2023-06-29 Steven Laplante Drug combinations for inhibiting coronavirus replication
WO2023170187A1 (en) * 2022-03-09 2023-09-14 Technische Universität München INHIBITION OF INTRACELLULAR PATHOGEN UPTAKE BY INHIBITORS OF THE IKK-α/NIK COMPLEX
CN116509874A (zh) * 2023-02-01 2023-08-01 潍坊医学院附属医院 甲基巴多索隆在制备改善病毒性心肌炎或病毒性心肌损伤的药物中的用途
CN118903154B (zh) * 2024-08-22 2025-11-11 中国农业科学院兰州兽医研究所(中国动物卫生与流行病学中心兰州分中心) 化合物CDDO-Im用于预防或治疗口蹄疫的新用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
CA2072758A1 (en) 1990-09-14 1992-03-15 Kenneth Francis Buechler Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
CA2107894C (en) 1991-04-10 2003-10-14 Kenneth F. Buechler Crosstalk inhibitors and their uses
EP0579767B1 (en) 1991-04-11 2000-08-23 Biosite Diagnostics Inc. Novel conjugates and assays for simultaneous detection of multiple ligands
US6019944A (en) 1992-05-21 2000-02-01 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
GB9212302D0 (en) 1992-06-10 1992-07-22 Applied Research Systems Method for improving measurement precision in evanescent wave optical biosensor assays
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6025395A (en) 1994-04-15 2000-02-15 Duke University Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US7176237B2 (en) 2002-01-15 2007-02-13 The Trustees Of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
EP2094651A1 (en) 2006-11-17 2009-09-02 Trustees Of Dartmouth College Synthesis and biological activities of new tricyclic-bis-enones (tbes)
ES2401741T3 (es) 2007-05-08 2013-04-24 Abbott Laboratories Ensayo de péptido natriurético de tipo B humano que tiene una reducida reactividad cruzada con otras formas péptidicas
US8088824B2 (en) 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
KR100905466B1 (ko) 2007-10-08 2009-07-02 한국과학기술원 차세대 셀룰라 통신시스템에서의 중계 통신방법
BRPI0907423A2 (pt) 2008-01-11 2020-10-27 Reata Pharmaceuticals, Inc. composto triterpenoide sintético para uso em um método de melhoria da função renal em um indivíduo, e uso do referido composto
WO2009146218A2 (en) 2008-04-18 2009-12-03 Reata Pharmaceuticals, Inc. Compounds including an anti-inflammatory pharmacore and methods of use
JP5529851B2 (ja) 2008-04-18 2014-06-25 リアタ ファーマシューティカルズ インコーポレイテッド 抗酸化炎症モジュレーター：ｃ−１７においてアミノ改変およびその他の改変を加えたオレアノール酸誘導体
KR101713140B1 (ko) 2008-04-18 2017-03-08 리타 파마슈티컬스 잉크. Ｃ-환에서 포화된 산화방지성 염증 조절제 올레아놀산 유도체
US8071632B2 (en) 2008-04-18 2011-12-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
MX2010011439A (es) 2008-04-18 2011-01-25 Reata Pharmaceuticals Inc Moduladores de inflamacion antioxidantes: derivados del acido oleanolico homologacion c-17.
SI2395979T1 (sl) 2009-02-13 2017-12-29 Reata Pharmaceuticals, Inc. Peroralni farmacevtski sestavki, ki vsebujejo amorfni CDDO-Me, z zapoznelim sproščanjem
DK2558105T3 (da) * 2010-04-12 2020-01-27 Reata Pharmaceuticals Inc Bardoxolonmethyl til behandling af fedme
CN102875634B (zh) 2012-10-24 2014-08-20 苏州晶云药物科技有限公司 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯的几种晶型
CN102887936A (zh) 2012-10-24 2013-01-23 苏州晶云药物科技有限公司 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯晶型
EP4736949A2 (en) * 2013-08-23 2026-05-06 Reata Pharmaceuticals Holdings, LLC Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
CN110198718B (zh) * 2016-11-08 2023-01-10 里亚塔医药控股有限责任公司 使用甲基巴多索隆或其类似物治疗阿尔波特综合征的方法
US11427533B2 (en) 2017-07-13 2022-08-30 Pliva Hrvatska D.O.O. Crystalline polymorphs of bardoxolone methyl
WO2021202547A1 (en) * 2020-04-01 2021-10-07 Triterpenoid Therapeutics, Inc. Methods and compositions for treating and preventing viral infection
WO2021202245A1 (en) * 2020-04-02 2021-10-07 Egaceutical Corporation Viral treatment regimens

Also Published As

Publication number Publication date
BR112022022599A2 (pt) 2023-03-21
MX2022014034A (es) 2023-01-11
EP4146226A1 (en) 2023-03-15
CN115803059A (zh) 2023-03-14
IL298008A (en) 2023-01-01
AU2021273460A1 (en) 2022-12-08
US20230255982A1 (en) 2023-08-17
WO2021231208A1 (en) 2021-11-18
JP2023526567A (ja) 2023-06-21
CA3177913A1 (en) 2021-11-18

Similar Documents

Publication Publication Date Title
AU2024200693B2 (en) Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof
US20240115542A1 (en) Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
KR20230022164A (ko) 바독솔론 메틸 또는 이의 유사체를 사용하여 covid-19를 치료하는 방법
EP3307262B1 (en) Compounds for use in treating neuromuscular disorders
WO2021226637A1 (en) Method of treating a patient infected with a coronavirus with nezulcitinib
WO2022271604A1 (en) Method of treating a patient infected with a coronavirus and having a baseline level of crp below 150 mg/l
KR20170034438A (ko) 통증 치료에서의 cyp2j2 길항제
CN115803059B (zh) 使用甲基巴多索隆或其类似物治疗covid-19的方法
HK40089696A (zh) 使用甲基巴多索隆或其类似物治疗covid-19的方法
HK40052300A (en) Methods of treating and preventing a renal disease using bardoxolone methyl or analogs thereof
HK40011743A (en) Methods of treating alport syndrome using bardoxolone methyl or analogs thereof
HK40011743B (en) Methods of treating alport syndrome using bardoxolone methyl or analogs thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902